Osteoarthritis News and Research

Latest Osteoarthritis News and Research

NAPRELAN Dose Card launched by Victory Pharma

Victory Pharma, Inc. ("Victory") announced today the launch of NAPRELAN® Dose Card, a further extension of Victory's NAPRELAN franchise.

23 Nov 2009

World Congress on Osteoporosis 2010: Researchers invited to contribute their abstracts

Researchers are invited to contribute their abstracts to the World Congress on Osteoporosis 2010 (IOF WCO - ECCEO10), the largest global meeting devoted to all aspects of osteoporosis and osteoarthritis research and patient care. The Congress will be held in Florence, Italy from May 5-8, 2010.

21 Nov 2009

Canadian Arthritis Network to host 2009 Annual Scientific Conference in Vancouver

People with arthritis and leading Canadian and international researchers will share the stage under the theme "Decoding Arthritis - A Joint Effort" when the Canadian Arthritis Network (CAN) hosts its 2009 Annual Scientific Conference beginning tonight, in Vancouver, BC.

19 Nov 2009

Anika Therapeutics' "ELEVESS Light" receives European CE Mark approval

Anika Therapeutics, Inc., a leader in products for tissue protection, healing and repair based on hyaluronic acid (“HA”) technology, today announced that it has received European CE Mark approval for “ELEVESS™ Light,” the Company’s latest aesthetic product used for the treatment of fine lines and facial wrinkles. ELEVESS Light will be distributed in the European market by the Company’s current aesthetic dermatology distributors.

19 Nov 2009

OA panel develops a consensus of the optimal exogenous HA treatment using BioRestorative Profiling

A panel of osteoarthritis (OA) key opinion leaders has developed a consensus of the optimal exogenous hyaluronic acid (HA) treatment. This consensus was achieved by utilizing what the experts referred to as BioRestorative(TM) Profiling. This profiling examines HAs on the basis of their mimicking the body's natural HA.

19 Nov 2009

New Drug Application for NicOx's naproxcinod accepted for filing

NicOx S.A. today announced that it has received a filing communication from the U.S. Food and Drug Administration (FDA) stating that the New Drug Application (NDA) for naproxcinod is accepted for filing. NicOx submitted the NDA on September 24th, seeking approval for the relief of the signs and symptoms of osteoarthritis.

18 Nov 2009

IntelGenx completes first successful human study of an anti-migraine film

IntelGenx Corp. is pleased to announce the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-migraine therapy. The product (INT008) has been developed using IntelGenx's proprietary immediate release film "VersaFilm" drug delivery technology. VersaFilm provides a patent-protected method of formulating in a convenient and discrete dosage form.

17 Nov 2009

Positive results from Winston Laboratories' Civamide Patch trial

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. today announced positive top-line results from Study WL1001-04-03, a Phase II clinical trial evaluating the safety and efficacy of the company's patch formulation of Civamide, a novel TRPV-1 receptor modulator in the treatment of post-herpetic neuralgia (PHN).

16 Nov 2009

Galapagos third quarter 2009 financial results in line with management expectations

Galapagos NV announces today that third quarter 2009 operational and financial results were in line with management expectations. These results encourage the Company to retain full year guidance of EUR 100 million revenues, a growth of 30% compared to 2008. Galapagos' service division BioFocus will significantly increase its cash contribution to the Group result for the full year 2009.

13 Nov 2009

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.

13 Nov 2009

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.

13 Nov 2009

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.

13 Nov 2009

Endo Pharmaceuticals reaches patent litigation settlement with LecTec

Endo Pharmaceuticals announced today that it has reached a settlement with LecTec Corporation on outstanding patent litigation related to LecTec's U.S. Patent Nos. 5,536,263 and 5,741,510.

11 Nov 2009

GeneNews discloses financial results for third-quarter 2009

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today reported operational and financial results for the third quarter-ended September 30, 2009.

11 Nov 2009

BioClinica to host a seminar on medical imaging for rheumatoid arthritis in clinical trials

BioClinica™, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced it will be hosting a seminar on November 18, 2009 highlighting new research, trends and updates from industry experts in rheumatoid arthritis. This event, which will be held in Lafayette, PA, is part of the continuing series of symposia hosted by the company for pharmaceutical and medical imaging executives over the past four years that addresses the challenges and approaches in conducting clinical trials.

From Clario 11 Nov 2009

Third quarter 2009 financial results announced by IntelGenx Technologies

IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCBB:IGXT) ("IntelGenx") today announced its results, reported in US dollars, for the three and nine months ended September 30, 2009.

10 Nov 2009

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Public health experts urge Congress not to overlook the needs of Americans with "morbid obesity"

As the House of Representatives and the Senate debate companion bills to make health care more affordable and accessible, a coalition of obesity and public health experts today urged Congress not to overlook the needs of the more than 15 million Americans who suffer from severe obesity and are at the greatest risk for chronic disease and death.

9 Nov 2009

FDA approves the New Drug Application for Pennsaid Topical Solution

Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.

5 Nov 2009

Pennsaid Topical Solution approved by FDA

Covidien, a leading global provider of healthcare products, and Nuvo Research Inc. (TSX:NRI), a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid® Topical Solution (diclofenac sodium topical solution) 1.5% w/w.

5 Nov 2009

Osteoarthritis News and Research

Latest Osteoarthritis News and Research

NAPRELAN Dose Card launched by Victory Pharma

World Congress on Osteoporosis 2010: Researchers invited to contribute their abstracts

Canadian Arthritis Network to host 2009 Annual Scientific Conference in Vancouver

Anika Therapeutics' "ELEVESS Light" receives European CE Mark approval

OA panel develops a consensus of the optimal exogenous HA treatment using BioRestorative Profiling

New Drug Application for NicOx's naproxcinod accepted for filing

IntelGenx completes first successful human study of an anti-migraine film

Positive results from Winston Laboratories' Civamide Patch trial

Galapagos third quarter 2009 financial results in line with management expectations

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

Endo Pharmaceuticals reaches patent litigation settlement with LecTec

GeneNews discloses financial results for third-quarter 2009

BioClinica to host a seminar on medical imaging for rheumatoid arthritis in clinical trials

Third quarter 2009 financial results announced by IntelGenx Technologies

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Public health experts urge Congress not to overlook the needs of Americans with "morbid obesity"

FDA approves the New Drug Application for Pennsaid Topical Solution

Pennsaid Topical Solution approved by FDA

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Osteoarthritis News and Research

Latest Osteoarthritis News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in